Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 264
Filter
1.
Chin Med J (Engl) ; 137(9): 1054-1068, 2024 May 05.
Article in English | MEDLINE | ID: mdl-38563217

ABSTRACT

BACKGROUND: Alterations in macular thickness and vascular density before clinically visible diabetic retinopathy (DR) remain inconclusive. This study aimed to determine whether retinal manifestations in abnormal glucose metabolism (AGM) patients differ from those in the healthy individuals. METHODS: PubMed, Embase, and Web of Science were searched between 2000 and 2021. The eligibility criteria were AGM patients without DR. Primary and secondary outcomes measured by optical coherence tomography (OCT) and OCT angiography (OCTA) were analyzed and expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs). A random-effects model was used in the data synthesis. The potential publication bias for the variables was evaluated using Egger's test. RESULTS: A total of 86 observational studies involving 13,773 participants and 15,416 eyes were included. OCT revealed that compared to healthy controls, the total macular thickness of AGM patients was thinner, including the thickness of fovea (-0.24, 95% CI [-0.39, -0.08]; P  = 0.002, I2  = 87.7%), all regions of parafovea (-0.32, 95% CI [-0.54, -0.11]; P  = 0.003; I2  = 71.7%) and the four quadrants of perifovea; the thickness of peripapillary retinal nerve fiber layer (pRNFL), macular retinal nerve fiber layer (mRNFL), and ganglion cell layer (GCL) also decreased. OCTA indicated that the superficial and deep vascular density decreased, the foveal avascular zone (FAZ) area enlarged, and the acircularity index (AI) reduced in AGM individuals. CONCLUSIONS: Retinal thinning and microvascular lesions have occurred before the advent of clinically detectable DR; OCT and OCTA may have the potential to detect these preclinical changes. REGISTRATION: PROSPERO; http://www.crd.york.ac.uk/prospero/ ; No. CRD42021269885.


Subject(s)
Macula Lutea , Tomography, Optical Coherence , Tomography, Optical Coherence/methods , Humans , Macula Lutea/diagnostic imaging , Macula Lutea/blood supply , Macula Lutea/metabolism , Diabetic Retinopathy/diagnostic imaging , Diabetic Retinopathy/metabolism , Glucose/metabolism , Retinal Vessels/diagnostic imaging , Retinal Vessels/pathology
2.
Invest Ophthalmol Vis Sci ; 65(1): 10, 2024 Jan 02.
Article in English | MEDLINE | ID: mdl-38170540

ABSTRACT

Purpose: Retinal pigment epithelium (RPE) cells show strong autofluorescence (AF). Here, we characterize the AF spectra of individual RPE cells in healthy eyes and those affected by age-related macular degeneration (AMD) and investigate associations between AF spectral response and the number of intracellular AF granules per cell. Methods: RPE-Bruch's membrane flatmounts of 22 human donor eyes, including seven AMD-affected eyes (early AMD, three; geographic atrophy, one; neovascular, three) and 15 unaffected macula (<51 years, eight; >80 years, seven), were imaged at the fovea, perifovea, and near-periphery using confocal AF microscopy (excitation 488 nm), and emission spectra were recorded (500-710 nm). RPE cells were manually segmented with computer assistance and stratified by disease status, and emission spectra were analyzed using cubic spline transforms. Intracellular granules were manually counted and classified. Linear mixed models were used to investigate associations between spectra and the number of intracellular granules. Results: Spectra of 5549 RPE cells were recorded. The spectra of RPE cells in healthy eyes showed similar emission curves that peaked at 580 nm for fovea and perifovea and at 575 and 580 nm for near-periphery. RPE spectral curves in AMD eyes differed significantly, being blue shifted by 10 nm toward shorter wavelengths. No significant association coefficients were found between wavelengths and granule counts. Conclusions: This large series of RPE cell emission spectra at precisely predefined retinal locations showed a hypsochromic spectral shift in AMD. Combining different microscopy techniques, our work has identified cellular RPE spectral AF and subcellular granule properties that will inform future in vivo investigations using single-cell imaging.


Subject(s)
Geographic Atrophy , Macula Lutea , Macular Degeneration , Humans , Retinal Pigment Epithelium/metabolism , Macular Degeneration/diagnosis , Macular Degeneration/metabolism , Bruch Membrane/metabolism , Geographic Atrophy/metabolism , Macula Lutea/metabolism
3.
Metabolomics ; 19(2): 10, 2023 02 06.
Article in English | MEDLINE | ID: mdl-36745234

ABSTRACT

INTRODUCTION: The primate retina has evolved regional specialisations for specific visual functions. The macula is specialised towards high acuity vision and is an area that contains an increased density of cone photoreceptors and signal processing neurons. Different regions in the retina display unique susceptibility to pathology, with many retinal diseases primarily affecting the macula. OBJECTIVES: To better understand the properties of different retinal areas we studied the differential distribution of metabolites across the retina. METHODS: We conducted an untargeted metabolomics analysis on full-thickness punches from three different regions (macula, temporal peri-macula and periphery) of healthy primate retina. RESULTS: Nearly half of all metabolites identified showed differential abundance in at least one comparison between the three regions. Furthermore, mapping metabolomics results from macula-specific eye diseases onto our region-specific metabolite distributions revealed differential abundance defining systemic metabolic dysregulations that were region specific. CONCLUSIONS: The unique metabolic phenotype of different retinal regions is likely due to the differential distribution of different cell types in these regions reflecting the specific metabolic requirements of each cell type. Our results may help to better understand the pathobiology of retinal diseases with region specificity.


Subject(s)
Macula Lutea , Retinal Diseases , Animals , Metabolomics , Retina/metabolism , Retinal Diseases/genetics , Retinal Diseases/metabolism , Macula Lutea/metabolism , Neurons/metabolism
4.
Int J Mol Sci ; 23(19)2022 Oct 04.
Article in English | MEDLINE | ID: mdl-36233066

ABSTRACT

Damage to the retinal pigment epithelium, Bruch's membrane and/or tissues underlying macula is known to increase the risk of age-related macular degeneration (AMD). AMD is commonly categorized in two distinct types, namely, the nonexudative (dry form) and the exudative (wet form). Currently, there is no ideal treatment available for AMD. Recommended standard treatments are based on the use of vascular endothelial growth factor (VEGF), with the disadvantage of requiring repeated intravitreal injections which hinder patient's compliance to the therapy. In recent years, several synthetic and natural active compounds have been proposed as innovative therapeutic strategies against this disease. There is a growing interest in the development of formulations based on nanotechnology because of its important role in the management of posterior eye segment disorders, without the use of intravitreal injections, and furthermore, with the potential to prolong drug release and thus reduce adverse effects. In the same way, 3D bioprinting constitutes an alternative to regeneration therapies for the human retina to restore its functions. The application of 3D bioprinting may change the current and future perspectives of the treatment of patients with AMD, especially those who do not respond to conventional treatment. To monitor the progress of AMD treatment and disease, retinal images are used. In this work, we revised the recent challenges encountered in the treatment of different forms of AMD, innovative nanoformulations, 3D bioprinting, and techniques to monitor the progress.


Subject(s)
Macula Lutea , Macular Degeneration , Bruch Membrane , Humans , Macula Lutea/metabolism , Macular Degeneration/drug therapy , Macular Degeneration/metabolism , Retinal Pigment Epithelium/metabolism , Vascular Endothelial Growth Factor A/metabolism
5.
Proc Natl Acad Sci U S A ; 119(15): e2200068119, 2022 04 12.
Article in English | MEDLINE | ID: mdl-35394870

ABSTRACT

Some mammalian tissues uniquely concentrate carotenoids, but the underlying biochemical mechanism for this accumulation has not been fully elucidated. For instance, the central retina of the primate eyes displays high levels of the carotenoids, lutein, and zeaxanthin, whereas the pigments are largely absent in rodent retinas. We previously identified the scavenger receptor class B type 1 and the enzyme ß-carotene-oxygenase-2 (BCO2) as key components that determine carotenoid concentration in tissues. We now provide evidence that Aster (GRAM-domain-containing) proteins, recently recognized for their role in nonvesicular cholesterol transport, engage in carotenoid metabolism. Our analyses revealed that the StART-like lipid binding domain of Aster proteins can accommodate the bulky pigments and bind them with high affinity. We further showed that carotenoids and cholesterol compete for the same binding site. We established a bacterial test system to demonstrate that the StART-like domains of mouse and human Aster proteins can extract carotenoids from biological membranes. Mice deficient for the carotenoid catabolizing enzyme BCO2 concentrated carotenoids in Aster-B protein-expressing tissues such as the adrenal glands. Remarkably, Aster-B was expressed in the human but not in the mouse retina. Within the retina, Aster-B and BCO2 showed opposite expression patterns in central versus peripheral parts. Together, our study unravels the biochemical basis for intracellular carotenoid transport and implicates Aster-B in the pathway for macula pigment concentration in the human retina.


Subject(s)
Carotenoids , Macula Lutea , Membrane Proteins , Animals , Biological Transport , Carotenoids/metabolism , Dioxygenases/genetics , Dioxygenases/metabolism , Humans , Macula Lutea/metabolism , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice
6.
Eur J Pharmacol ; 914: 174663, 2022 Jan 05.
Article in English | MEDLINE | ID: mdl-34861209

ABSTRACT

We have earlier demonstrated that lutein effectively prevents hyperglycemia generated sustained oxidative stress in ARPE-19 cells by activating Nrf2 (nuclear factor erythroid 2-related factor 2) signaling. Since evidence portrays an intricate connection between ER (endoplasmic reticulum) stress and hyperglycemia-mediated oxidative stress, we aimed to explore the protective mechanism of lutein on hyperglycemia-induced ER stress in ARPE-19 cells. To determine the effect of lutein, we probed three major downstream branches of unfolded protein response (UPR) signaling pathways using western blot, immunofluorescent and RT-PCR techniques. The data showed a reduction (38%) in protein expression of an imperative ER chaperon, BiP (binding immunoglobulin protein), in glucose-treated ARPE-19 cells. At the same time, lutein pretreatment blocked this glucose-mediated effect, leading to a significant increase in BiP expression. Lutein promoted the phosphorylation of IRE1 (inositol requiring enzyme 1) and subsequent splicing of XBP1 (X-box binding protein 1), leading to enhanced nuclear translocation. Likewise, lutein activated the expression and translocation of transcription factors, ATF6 (activating transcription factor 6) and ATF4 (activating transcription factor 4) suppressed by hyperglycemia. Lutein also increased CHOP (C/EBP-homologous protein) levels in ARPE-19 cultured under high glucose conditions. The mRNA expression study showed that lutein pretreatment upregulates downstream UPR genes HRD1 (ERAD-associated E3 ubiquitin-protein ligase HRD1), p58IPK (protein kinase inhibitor p58) compared to high glucose treatment alone. From our study, it is clear that lutein show protection against hyperglycemia-mediated ER stress in ARPE-19 cells by activating IRE1-XBP1, ATF6, and ATF4 pathways and their downstream activators. Thus, lutein may have the pharmacological potential for protection against widespread disease conditions of ER stress.


Subject(s)
Endoplasmic Reticulum Stress/drug effects , Gene Expression Regulation/drug effects , Hyperglycemia/metabolism , Lutein/pharmacology , Signal Transduction/drug effects , Unfolded Protein Response/drug effects , Activating Transcription Factor 4/metabolism , Activating Transcription Factor 6/metabolism , Biological Factors/pharmacology , Cell Line , Endoribonucleases/metabolism , Humans , Hyperglycemia/complications , Macula Lutea/metabolism , Macula Lutea/pathology , Oxidative Stress , Protective Agents/pharmacology , Protein Serine-Threonine Kinases/metabolism , X-Box Binding Protein 1/metabolism
7.
Nutrients ; 13(12)2021 Dec 09.
Article in English | MEDLINE | ID: mdl-34959963

ABSTRACT

Age-related macular degeneration (AMD) is the third leading cause of blindness worldwide. Macular pigment optical density (MPOD), a biomarker for AMD, is a non-invasive measure to assess risk. The macula xanthophyll pigments lutein (L) and zeaxanthin (Z) protect against blue light and provide oxidant defense, which can be indexed by MPOD. This study examined the effects of Z-rich goji berry intake on MPOD and skin carotenoids in healthy individuals. A randomized, unmasked, parallel-arm study was conducted with 27 participants, aged 45-65, who consumed either 28 g of goji berries or a supplement containing 6 mg L and 4 mg Z (LZ), five times weekly for 90 days. After 90 days, MPOD was significantly increased in the goji berry group at 0.25 and 1.75 retinal eccentricities (p = 0.029 and p = 0.044, respectively), while no changes were noted in the LZ group. Skin carotenoids were significantly increased in the goji berry group at day 45 (p = 0.025) and day 90 (p = 0.006), but not in the LZ group. Regular intake of goji berries in a healthy middle-aged population increases MPOD may help prevent or delay the development of AMD.


Subject(s)
Dietary Supplements , Eating/physiology , Lutein/metabolism , Lycium , Macula Lutea/metabolism , Macular Degeneration/prevention & control , Macular Pigment/metabolism , Zeaxanthins/metabolism , Aged , Carotenoids/metabolism , Female , Healthy Volunteers , Humans , Macular Degeneration/metabolism , Male , Middle Aged , Pilot Projects , Skin/metabolism
8.
Front Immunol ; 12: 738521, 2021.
Article in English | MEDLINE | ID: mdl-34721402

ABSTRACT

Background: Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness in older people. Low-grade inflammation is well-known as one of the pathogenic mechanisms in nAMD. Anti-vascular endothelial growth factor (VEGF) therapy is the first-line treatment for nAMD, although macula atrophy (MA) developed under anti-VEGF therapy causes irreversible visual function impairment and is recognized as a serious disorder. Here, we show specific expression patterns of aqueous humor (AH) cytokines in nAMD eyes developing MA under intravitreal injection of aflibercept (IVA) as an anti-VEGF antibody and present predictive cytokines as biomarkers for the incidence of MA in nAMD eyes under IVA treatment. Methods: Twenty-eight nAMD patients received three consecutive monthly IVA, followed by a pro re nata regimen for 2 years. AH specimens were collected before first IVA (pre-IVA) and before third IVA (post-IVA). AH cytokine levels, visual acuity (VA), and central retinal thickness (CRT) were measured. Results: Two-year incidence of MA was 21.4%. In nAMD eyes developing MA [MA (+) group], pre-IVA levels of monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1ß, VEGF and post-IVA level of MCP-1 were higher than those in nAMD eyes without MA [MA (-) group]. In hierarchical cluster analysis, pre-IVA MCP-1 and VEGF were grouped into the same subcluster, as were post-IVA MCP-1 and CRT. In principal component analysis, principal component loading (PCL) of pre-IVA interferon-γ-inducible protein 10 (IP-10) was 0.61, but PCL of post-IVA IP-10 decreased to -0.09. In receiver operating characteristic analysis and Kaplan-Meier curves, pre-IVA MCP-1, MIP-1ß, and VEGF and post-IVA interleukin-6, MCP-1, and MIP-1ß were detected as predictive factors for MA incidence. In 2-year clinical course, changes of VA in groups with high levels of pre-IVA MIP-1ß (over 39.9 pg/ml) and VEGF (over 150.4 pg/ml) were comparable to those in MA (+) group. Conclusion: Substantial loss of IP-10 effects and persistent inflammation contribute to incidence of MA, and screening of AH cytokine levels could be a useful method to predict MA incidence in nAMD eyes under anti-VEGF therapy.


Subject(s)
Angiogenesis Inhibitors/adverse effects , Aqueous Humor/metabolism , Cytokines/metabolism , Inflammation Mediators/metabolism , Macula Lutea/drug effects , Macular Degeneration/drug therapy , Recombinant Fusion Proteins/adverse effects , Retinal Neovascularization , Adult , Aged , Aged, 80 and over , Angiogenesis Inhibitors/administration & dosage , Aqueous Humor/immunology , Atrophy , Biomarkers/metabolism , Female , Humans , Intravitreal Injections , Macula Lutea/immunology , Macula Lutea/metabolism , Macula Lutea/pathology , Macular Degeneration/immunology , Macular Degeneration/metabolism , Macular Degeneration/pathology , Male , Middle Aged , Prospective Studies , Receptors, Vascular Endothelial Growth Factor/administration & dosage , Recombinant Fusion Proteins/administration & dosage , Time Factors , Treatment Outcome , Visual Acuity/drug effects
9.
Nutrients ; 13(9)2021 Sep 14.
Article in English | MEDLINE | ID: mdl-34579067

ABSTRACT

Twilight and low luminance levels are visually challenging environments for the elderly, especially when driving at night. Carotenoid rich diets are known to increase macular pigment optical density (MPOD), which in turn leads to an improvement in visual function. It is not known whether augmenting MPOD can lead to a decrease in vision related night driving difficulties. Additionally, it is unknown if carotenoid supplementation provides additional measurable benefits to one's useful field of view (UFOV) along with a decreased composite crash risk score. The aim of the study was to evaluate changes in night vision function and UFOV in individuals that took carotenoid vitamin supplements for a six-month period compared to a placebo group. METHODS: A prospective, randomized, double-blind, six-month trial of a 14 mg zeaxanthin/7 mg lutein-based supplement was carried out. Participants were randomized into active or placebo group (approx 2:1). RESULTS: n = 33 participants (26 males/7 females) participated with 93% capsule intake compliance in the supplemented group (n = 24) and placebo group (n = 9). MPOD (mean/standard error SE) in the active group increased in the Right eye from 0.35 density units (du)/0.04 SE to 0.41 du/0.05 SE; p < 0.001 and in the Left eye from 0.35 du/0.05 SE to 0.37 du, p > 0.05). The supplemented group showed significant improvements in contrast sensitivity with glare in both eyes with improvements in LogMAR scores of 0.147 and 0.149, respectively (p = 0.02 and 0.01, respectively), monocularly tested glare recovery time improved 2.76 and 2.54 s, respectively, (p = 0.008 and p = 0.02), and we also noted a decreased preferred luminance required to complete visual tasks (p = 0.02 and 0.03). Improvements in UFOV scores of divided attention (p < 0.001) and improved composite crash risk score (p = 0.004) were seen in the supplemented group. The placebo group remained unchanged. CONCLUSIONS: The NVC demonstrates that augmenting MPOD in individuals with difficulty in night vision showed measurable benefits in numerous visual functions that are important for night vision driving in this small sample RCT. Additionally, we observed an improvement in UFOV divided attention test scores and decreased composite risk scores.


Subject(s)
Dietary Supplements , Lutein/pharmacology , Macular Pigment/metabolism , Night Vision/drug effects , Vision, Ocular/drug effects , Visual Acuity/drug effects , Zeaxanthins/pharmacology , Accidents, Traffic/prevention & control , Aged , Automobile Driving , Double-Blind Method , Female , Humans , Macula Lutea/drug effects , Macula Lutea/metabolism , Macular Degeneration , Male , Middle Aged , Prospective Studies , Visual Field Tests
10.
Invest Ophthalmol Vis Sci ; 62(9): 20, 2021 07 01.
Article in English | MEDLINE | ID: mdl-34254974

ABSTRACT

Purpose: We investigated whether dietary carotenoids lutein and zeaxanthin (L/Z) in the serum and macula were associated with central retinal arteriole and venule calibers in a follow-up ancillary study among older women in the Women's Health Initiative. Methods: Among 390 women who participated in Carotenoids in Age-Related Eye Disease Study 2 (CAREDS2) (2016-2019), we investigated associations between serum L/Z at Women's Health Initiative baseline (1994-1998), and macular pigment optical density (MPOD) at CAREDS baseline (2001-2004), with central retinal vessel caliber in CAREDS2. MPOD was measured using heterochromatic flicker photometry (0.5° from the foveal center) in CAREDS baseline and CAREDS2. Vessel calibers were measured from fundus photographs (CAREDS2). We also explored associations in women with stable MPOD (±0.10 optical density units) over 15 years (n = 106), given the long-term increases in MPOD related to diet patterns and supplement use. Associations were investigated using linear modeling. Results: In the full sample (n = 390), higher serum L/Z (tertile 3 vs. 1) was positively associated with arteriole caliber (mean ± SE, 145.0 ± 1.4 µm vs. 140.8 ± 1.4 µm; P = 0.05) and venule caliber (214.6 ± 2.2 µm vs. 207.5 ± 2.2 µm; P = 0.03). MPOD was also associated with wider vessel calibers (tertile 3 vs. 1), but the trend was only statistically significant for venules (144.4 ± 1.4 µm vs. 141.1 ± 1.4 µm [P = 0.12] and 213.3 ± 2.1 µm vs. 206.0 ± 2.1 µm [P = 0.02], respectively.) Most associations were strengthened in women with stable MPOD over 15 years, including between MPOD and arteriole caliber (149.8 ± 2.6 µm vs.135.8 ± 3.0 µm; P = 0.001). Conclusions: Higher L/Z status in serum and retina was associated with larger central retinal vessel calibers. Prospective studies and clinical trials are needed to elucidate whether L/Z supplementation prevents vision loss through increasing blood flow.


Subject(s)
Carotenoids/metabolism , Forecasting , Macula Lutea/metabolism , Macular Degeneration/metabolism , Retinal Vessels/physiopathology , Visual Acuity , Aged , Aged, 80 and over , Biomarkers/metabolism , Disease Progression , Female , Follow-Up Studies , Humans , Macula Lutea/pathology , Macular Degeneration/diagnosis , Macular Degeneration/physiopathology , Male , Prospective Studies , Retinal Pigments/metabolism , Retinal Vessels/metabolism , Retinal Vessels/pathology
11.
Sci Rep ; 11(1): 15393, 2021 07 28.
Article in English | MEDLINE | ID: mdl-34321574

ABSTRACT

Many studies have demonstrated that rhegmatogenous retinal detachment (RRD) leads to impaired retinal circulation. However, the involvement of inflammation in the RRD-induced worsening of retinal circulation was obscure. This retrospective observational study included 150 patients with primary RRD (macula-on, n = 63; macula-off, n = 87) who underwent 25-gauge microincision vitrectomy surgery (25G MIVS). Total retinal blood flow was represented by the mean blur rate (MBR) of the optic nerve head vessel, measured by laser speckle flowgraphy preoperatively and until 6 months postoperatively. Aqueous humor samples were obtained during surgery to determine cytokine concentrations by enzyme-linked immunosorbent assay. At 3 and 6 months postoperatively, there were no significant differences between eyes with macula-on RRD and fellow eyes. However, in macula-off RRD, MBR remained significantly lower in RRD eyes 6 months postoperatively (P < 0.05). Log-transformed levels of soluble intercellular adhesion molecule-1 (sICAM-1) were negatively correlated with relative MBR (r-MBR, RRD eye/fellow eye) before surgery (r = - 0.47, P = 0.01) in macula-on, but not macula-off, RRD. Six months postoperatively, r-MBR correlated significantly with sICAM-1 levels (r = - 0.36, P = 0.02) in macula-off RRD. ICAM-1 may play a role in RRD-induced deterioration of retinal circulation.


Subject(s)
Eye Diseases, Hereditary/genetics , Intercellular Adhesion Molecule-1/genetics , Macula Lutea/metabolism , Retina/metabolism , Retinal Detachment/genetics , Eye Diseases, Hereditary/blood , Eye Diseases, Hereditary/pathology , Eye Diseases, Hereditary/surgery , Female , Humans , Intercellular Adhesion Molecule-1/blood , Macula Lutea/blood supply , Macula Lutea/pathology , Macula Lutea/surgery , Male , Middle Aged , Optic Disk/metabolism , Optic Disk/pathology , Retina/pathology , Retina/surgery , Retinal Detachment/blood , Retinal Detachment/pathology , Retinal Detachment/surgery , Tomography, Optical Coherence , Visual Acuity/genetics , Visual Acuity/physiology , Vitrectomy
12.
PLoS One ; 16(5): e0251324, 2021.
Article in English | MEDLINE | ID: mdl-34043644

ABSTRACT

INTRODUCTION: The dietary carotenoids lutein (L) and zeaxanthin (Z) are transported in the bloodstream by lipoproteins, sequestered by adipose tissue, and eventually captured in the retina where they constitute macular pigment. There are no L&Z dietary intake recommendations nor desired blood/tissue concentrations for the Spanish general population. Our aim was to assess the correlation of L&Z habitual dietary intake (excluding food supplements), resulting serum concentrations and lipid profile with macular pigment optical density (MPOD) as well as the contrast sensitivity (CT), as visual outcome in normolipemic subjects (n = 101) aged 45-65. METHODS: MPOD was measured by heterochromatic flicker photometry, serum L&Z by HPLC, the dietary intake by a 3-day food records and CT using the CGT-1000-Contrast-Glaretester at six stimulus sizes, with and without glare. RESULTS: Lutein and zeaxanthin concentrations (median) in serum: 0.361 and 0.078 µmol/L, in dietary intake: 1.1 mg L+Z/day. MPOD: 0.34du. L+Z intake correlates with their serum concentrations (rho = 0.333, p = 0.001), which in turn correlates with MPOD (rho = 0.229, p = 0.000) and with fruit and vegetable consumption (rho = 0.202, p = 0.001), but not with lutein+zeaxanthin dietary intake. MPOD correlated with CT, with and without glare (rho ranges: -0.135, 0.160 and -0.121, -0.205, respectively). MPOD predictors: serum L+Z, L+Z/HDL-cholesterol (ß-coeficient: -0.91±0.2, 95%CI: -1.3,-0.5) and HDL-cholesterol (R2 = 15.9%). CT predictors: MPOD, mainly at medium and smaller visual angles (corresponding to spatial frequencies for which sensitivity declines with age) and gender (ß-coefficients ranges: -0.95,-0.39 and -0.13,-0.39, respectively). CONCLUSION: A higher MPOD is associated with a lower ratio of L+Z/HDL-cholesterol and with a lower CT (higher contrast sensitivity). The HDL-cholesterol would also act indirectly on the CT improving the visual function.


Subject(s)
Contrast Sensitivity/drug effects , Eating/physiology , Macular Pigment/metabolism , Cholesterol, HDL/metabolism , Diet , Dietary Supplements , Female , Glare , Healthy Volunteers , Humans , Lipids/blood , Lipoproteins/metabolism , Lutein/administration & dosage , Macula Lutea/drug effects , Macula Lutea/metabolism , Male , Middle Aged , Retina/drug effects , Retina/metabolism , Vision, Ocular/drug effects , Zeaxanthins/administration & dosage
13.
Int J Mol Sci ; 22(7)2021 Mar 26.
Article in English | MEDLINE | ID: mdl-33810342

ABSTRACT

The retinal ganglion cells (RGC) may be considered an easily accessible pathophysiological site of degenerative processes in neurological diseases, such as the RGC damage detectable in multiple sclerosis (MS) patients with (HON) and without a history of optic neuritis (NON). We aimed to assess and interrelate RGC functional and structural damage in different retinal layers and retinal sites. We included 12 NON patients, 11 HON patients and 14 healthy controls for cross-sectional multifocal pattern electroretinography (mfPERG) and optical coherence tomography (OCT) measurements. Amplitude and peak times of the mfPERG were assessed. Macula and disc OCT scans were acquired to determine macular retinal layer and peripapillary retinal nerve fiber layer (pRNFL) thickness. In both HON and NON patients the foveal N2 amplitude of the mfPERG was reduced compared to controls. The parafoveal P1 peak time was significantly reduced in HON only. For OCT, parafoveal (pfGCL) and perifoveal (pGCL) ganglion cell layer thicknesses were decreased in HON vs. controls, while pRNFL in the papillomacular bundle sector (PMB) showed reductions in both NON and HON. As the mfPERG derived N2 originates from RGC axons, these findings suggest foveal axonal dysfunction not only in HON, but also in NON patients.


Subject(s)
Multiple Sclerosis/metabolism , Optic Neuritis/metabolism , Retinal Ganglion Cells/metabolism , Adult , Algorithms , Axons/metabolism , Case-Control Studies , Electroretinography , Female , Humans , Macula Lutea/metabolism , Male , Middle Aged , Multiple Sclerosis/diagnostic imaging , Optic Disk/diagnostic imaging , Prospective Studies , Recurrence , Structure-Activity Relationship , Tomography, Optical Coherence , Young Adult
14.
Sci Rep ; 11(1): 4488, 2021 02 24.
Article in English | MEDLINE | ID: mdl-33627712

ABSTRACT

This prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic macula edema (DME) patients. We examined 40 eyes (40 adults) with fovea-involving DME from 8 Japanese centers between April 2015 and February 2017. Participants received IAI with an induction period featuring monthly injections and a subsequent T&E period featuring 8-16-week injection interval, adjusted based on optical coherence tomography findings. The primary endpoints were mean changes in the best-corrected visual acuity (BCVA) and central subfield macular thickness (CST) from baseline. Thirty patients (75%) completed the 2-year follow-up. The mean BCVA and CST changed from 60.5 ± 15.6 letters and 499.2 ± 105.6 µm at baseline to 66.6 ± 17.1 letters (P = 0.217) and 315.2 ± 79.0 µm (P < 0.001), respectively, after 2 years. The treatment interval was extended to 12 and 16 weeks in 6.7% and 66.7% of patients, respectively, at the end of 2 years. The T&E aflibercept regimen with the longest treatment interval set to 16 weeks, with adjunct focal/grid laser may be a rational 2-year treatment strategy for DME.


Subject(s)
Diabetic Retinopathy/drug therapy , Macula Lutea/drug effects , Macular Edema/drug therapy , Receptors, Vascular Endothelial Growth Factor/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Aged , Angiogenesis Inhibitors/therapeutic use , Diabetes Mellitus/metabolism , Diabetic Retinopathy/metabolism , Female , Humans , Intravitreal Injections , Laser Coagulation/methods , Macula Lutea/metabolism , Macular Edema/metabolism , Male , Prospective Studies , Tomography, Optical Coherence/methods , Treatment Outcome , Vascular Endothelial Growth Factor A/metabolism , Visual Acuity/drug effects
16.
Acta Ophthalmol ; 99(7): 790-796, 2021 Nov.
Article in English | MEDLINE | ID: mdl-33416216

ABSTRACT

PURPOSE: Metabolic and structural microvascular retinal alterations are essential components in diabetic retinopathy (DR). The present study aimed to measure changes at different stages of non-proliferative DR (NPDR) and to explore interactions of imaging-based metrics. METHODS: This cross-sectional, cohort study included 139 eyes from 80 diabetic patients. Each patient underwent dilated fundal examinations including colour fundus photography, retinal oximetry and optical coherence tomography angiography (OCTA), analysed by semi-automated and automated software. Diabetic retinopathy (DR) severity was classified according to the International Clinical Diabetic Retinopathy (ICDR) Severity Scale, ranging from no DR to severe NPDR (level 0-3). Retinal metabolism was evaluated by oximetry as retinal arteriolar (raSatO2 ) and venular oxygen saturation (rvSatO2 ), and macular microvascular structure was measured by OCTA as the area of foveal avascular zone (FAZ), vessel density (VD), vessel diameter index (VDI), FAZ circularity and fractal dimension (FD) in the superficial and deep retinal capillary plexus. RESULTS: A trend for increasing rvSatO2 was found with increasing DR severity (51.3%, 53.3%, 54.2%, 59.8%, p = 0.02). Increasing severity of DR associated with decreasing FD in the superficial and deep plexus (p < 0.001 and p = 0.014), and in the superficial plexus decreasing VD (p < 0.001), increasing VDI (p = 0.003) and decreasing FAZ circularity (p = 0.006). A few interactions were identified between raSatO2 , rvSatO2 and VDI, but only in the deep capillary plexus (p < 0.01 and p < 0.01). CONCLUSION: Alterations of the venular retinal vascular oxygen saturation and microvascular structural abnormities were found continuously throughout the DR-spectrum. Given the sparse correlations between metabolic and structural abnormalities, it seems that these occur independently in DR.


Subject(s)
Diabetic Retinopathy/diagnosis , Macula Lutea/blood supply , Oxygen Saturation/physiology , Oxygen/analysis , Retinal Vessels/physiopathology , Cross-Sectional Studies , Diabetic Retinopathy/metabolism , Diabetic Retinopathy/physiopathology , Female , Fluorescein Angiography/methods , Follow-Up Studies , Fundus Oculi , Humans , Macula Lutea/metabolism , Male , Middle Aged , Retinal Vessels/metabolism , Tomography, Optical Coherence/methods
17.
Ann Biomed Eng ; 49(1): 251-261, 2021 Jan.
Article in English | MEDLINE | ID: mdl-32458221

ABSTRACT

Age-related macular degeneration (AMD) is the leading cause of central vision loss in the developed world. Wet AMD can be managed through serial intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents. However, sometimes the treatment is ineffective. Given that the half-life of the drug is limited, inefficient mixing of the injected drug in the vitreous chamber of the eye may contribute to the ineffectiveness. Here, we introduce thermal heating as a means of enhancing the mixing-process in the vitreous chamber and investigate parameters that potentially influence its effectiveness. Our in vitro studies reveal the importance of the heating location on the eye. A significant increase in the mixing and delivery of drugs to the targeted area (the macula) could be achieved by placing heating pads to induce a current, against gravity, in the vitreous. The presented results can potentially help in the development of a better strategy for intravitreal injection, subsequently improving the quality of patient care.


Subject(s)
Drug Delivery Systems , Hot Temperature , Models, Biological , Vitreous Body , Fluorescein/administration & dosage , Glycerol/administration & dosage , Humans , Intravitreal Injections , Macula Lutea/metabolism , Water/administration & dosage , Wet Macular Degeneration/drug therapy
18.
Retin Cases Brief Rep ; 15(1): 81-83, 2021 Jan 01.
Article in English | MEDLINE | ID: mdl-29528887

ABSTRACT

PURPOSE: To present a case of crystalline retinopathy associated with chronic retinal detachment and localize the macular crystals using spectral domain optical coherence tomography. METHODS: Case Report. RESULTS: A 37-year-old man with previously treated chronic retinal detachment presented with normal vision and crystalline maculopathy. Spectral domain optical coherence tomography localized the macular crystals to the posterior hyaloid membrane and on the internal limiting membrane, but not within the retina. CONCLUSION: The macular crystals in crystalline retinopathy associated with chronic retinal detachment most likely originate in the subretinal space beneath the detached retina, migrate through the retinal break into the vitreous cavity, and lodge on the surface of the internal limiting membrane. When the posterior hyaloid membrane separates, the crystals, which are attached to the posterior hyaloid membrane, elevate from the retina.


Subject(s)
Eye Proteins/metabolism , Macula Lutea/metabolism , Retinal Detachment/diagnosis , Tomography, Optical Coherence/methods , Visual Acuity , Adult , Chronic Disease , Crystallization , Humans , Macula Lutea/pathology , Male , Retinal Detachment/metabolism , Retinal Detachment/surgery , Vitrectomy/methods
19.
Proc Natl Acad Sci U S A ; 117(48): 30661-30669, 2020 12 01.
Article in English | MEDLINE | ID: mdl-33168747

ABSTRACT

Microglia are resident central nervous system macrophages and the first responders to neural injury. Until recently, microglia have been studied only in animal models with exogenous or transgenic labeling. While these studies provided a wealth of information on the delicate balance between neuroprotection and neurotoxicity within which these cells operate, extrapolation to human immune function has remained an open question. Here we examine key characteristics of retinal macrophage cells in live human eyes, both healthy and diseased, with the unique capabilities of our adaptive optics-optical coherence tomography approach and owing to their propitious location above the inner limiting membrane (ILM), allowing direct visualization of cells. Our findings indicate that human ILM macrophage cells may be distributed distinctly, age differently, and have different dynamic characteristics than microglia in other animals. For example, we observed a macular pattern that was sparse centrally and peaked peripherally in healthy human eyes. Moreover, human ILM macrophage density decreased with age (∼2% of cells per year). Our results in glaucomatous eyes also indicate that ILM macrophage cells appear to play an early and regionally specific role of nerve fiber layer phagocytosis in areas of active disease. While we investigate ILM macrophage cells distinct from the larger sample of overall retinal microglia, the ability to visualize macrophage cells without fluorescent labeling in the live human eye represents an important advance for both ophthalmology and neuroscience, which may lead to novel disease biomarkers and new avenues of exploration in disease progression.


Subject(s)
Macrophages/metabolism , Molecular Imaging , Optical Imaging , Retina/metabolism , Retina/pathology , Biomarkers , Disease Susceptibility , Glaucoma/diagnosis , Glaucoma/etiology , Glaucoma/metabolism , Humans , Macrophages/immunology , Macula Lutea/metabolism , Microglia/immunology , Microglia/metabolism , Microglia/pathology , Molecular Imaging/methods , Neuroprotection , Optical Imaging/methods , Retina/diagnostic imaging , Tomography, Optical Coherence
20.
Int J Mol Sci ; 21(22)2020 Nov 21.
Article in English | MEDLINE | ID: mdl-33233417

ABSTRACT

In the sub-retinal pigment epithelium (sub-RPE) space of the aging macula, deposits of oxidized phospholipids, oxidized derivatives of cholesterol and associated oxidized low-density lipoproteins (OxLDL) are considered contributors to the onset and development of age-related macular degeneration (AMD). We investigated the gene expression response of a human-derived RPE cell line exposed for short periods of time to non-cytotoxic levels of OxLDL or LDL. In our cell model, treatment with OxLDL, but not LDL, generated an early gene expression response which affected more than 400 genes. Gene pathway analysis unveiled gene networks involved in the regulation of various cellular functions, including acute response to oxidative stress via up-regulation of antioxidative gene transcripts controlled by nuclear factor erythroid-2 related factor 2 (NRF2), and up-regulation of aryl hydrocarbon receptor-controlled detoxifying gene transcripts. In contrast, circadian rhythm-controlling genes and genes involved in lipid metabolism were strongly down-regulated. Treatment with low-density lipoprotein (LDL) did not induce the regulation of these pathways. These findings show that RPE cells are able to selectively respond to the oxidized forms of LDL via the up-regulation of gene pathways involved in molecular mechanisms that minimize cellular oxidative damage, and the down-regulation of the expression of genes that regulate the intracellular levels of lipids and lipid derivatives. The effect on genes that control the cellular circadian rhythm suggests that OxLDL might also disrupt the circadian clock-dependent phagocytic activity of the RPE. The data reveal a complex cellular response to a highly heterogeneous oxidative stress-causing agent such as OxLDL commonly present in drusen formations.


Subject(s)
Aging/genetics , Lipoproteins, LDL/metabolism , Macular Degeneration/genetics , NF-E2-Related Factor 2/genetics , Receptors, Aryl Hydrocarbon/genetics , Aging/pathology , Cell Line , Cholesterol/metabolism , Cholesterol, LDL/genetics , Cholesterol, LDL/pharmacology , Gene Expression Regulation/genetics , Humans , Lipoproteins, LDL/genetics , Macula Lutea/metabolism , Macula Lutea/pathology , Macular Degeneration/drug therapy , Macular Degeneration/metabolism , Macular Degeneration/pathology , NF-E2-Related Factor 2/metabolism , Oxidative Stress/drug effects , Phospholipids/metabolism , Retinal Pigment Epithelium/metabolism , Retinal Pigment Epithelium/pathology , Transcriptome/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...